Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...

Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

The 6-food elimination diet (SFED) is the most cost-effective first-line treatment for eosinophilic esophagitis (EoE) from a financial standpoint. However, proton pump inhibitors (PPIs) are the most ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been ...